A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.
作者： Tin Aung , Paul T.K Chew , Chee-Chew Yip , Yiong-Huak Chan , Jovina L.S See
DOI: 10.1016/S0002-9394(00)00943-0
关键词:
摘要: PURPOSE: To compare the intraocular pressure)–lowering effect and side effects of latanoprost 0.005% once daily with unoprostone 0.12% twice daily. METHODS: Sixty patients primary open-angle glaucoma or ocular hypertension were randomized to receive either in evening placebo morning, morning evening. The study was double masked followed a crossover design two treatment periods 1 month separated by 3-week washout period. pressure measured at 9 am 5 pm on baseline day 28 visits, 2 14 visits each measurement taken hours 13 after last drop latanoprost, 10 21 hours, respectively. mean measurements calculated. Safety parameters also recorded. RESULTS: Fifty-six completed both had data available for evaluation. After treatment, significantly reduced (mean ± SEM) 6.1 0.5 mm Hg (P < .001) 4.2 0.4 adjusted from an overall 22.3 23.2 Hg, difference 1.9 between treatments statistically significant favor [P = .003, analysis covariance (ANCOVA)]. Unadjusted responders using percentage decrease showed that proportion latanoprost-treated group greater than unoprostone-treated group. Adverse symptoms findings mild groups. Eye redness irritation most frequently reported events. CONCLUSIONS: Latanoprost more effective reducing compared hypertension. Both drugs well tolerated few adverse events.
elsevier.com
sci-hub.se 参考文章(17)
Ronald E. Warwar, John D. Bullock, Deepti Ballal, Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients Ophthalmology. ,vol. 105, pp. 263- 268 ,(1998) , 10.1016/S0161-6420(98)92977-3
Albert Alm, Johan Stjernschantz, Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group Ophthalmology. ,vol. 102, pp. 1743- 1752 ,(1995) , 10.1016/S0161-6420(95)30798-1
David Machin, Michael J Campbell, Say Beng Tan, Sze Huey Tan, Sample Size Tables for Clinical Studies ,(1997)
J Serle, A Comparative Study of Latanoprost (Xalatan) and Isopropyl Unoprostone (Rescula) in Normal and Glaucomatous Monkey Eyes Japanese Journal of Ophthalmology. ,vol. 42, pp. 95- 100 ,(1998) , 10.1016/S0021-5155(97)00128-7
C.J. Pollack-Rundle, C.B. Camras, E. Weiss, M.E. Yablonski, M.H. Tannenbaum, F. Ibrahim, E. Ohia, D. Neeley, D. Minckler, D. Heuer, P. Lee, M. Padea, P.L. Kaufman, G.A. Heatley, M.A. Vanderhof-Young, M. Wax, A. Jones, L.J. Katz, M. Moster, B. Parker, A.L. Robin, M. Juzych, M. Brummett, Carl B. Camras, Albert Alm, Peter Watson, Johan Stjernschantz, H. Aasved, P. Jangard, H. Lund-Andersen, P. Flesner, M. Söderström, B. Ehinger, C. Holmin, E. Bengtsson-Stigmar, A. Heijl, K.G. Gundersen, J. Airaksinen, A. Tuulonen, R. Halseide, B. Lindblom, A. Ringvold, A. Vegge, C. Linden, S.E. Nilsson, B. Friström, A. Alm, I. Widengard, J. Thygesen, F. Green, F. Valenzuela, P. Watson, M. Potts, I. Spencer, R. Coakes, P. Reynolds, B. Mills, A. Chatterjee, S. Nagasubramanian, S. Roxburgh, R. Sanders, M. Bailey, I.F. Whyte, S. Vernon, M. Sloper, S. Murray, C. Davey, J. Hickman-Casey, S. Longstaff, Z. Currie, P. Wishart, M. Austin, M. Birch, A. Elkington, A. Luff, L. Beck, M. Blackmore, G.A. Cioffi, E.M. Van Buskirk, J. Fraser, W.C. Stewart, J.A. Stewart, J. Lustgarten, R.A. Schumer, S.M. Podos, M. Arroyo, S. Nitzberg, R. Ritch, G. Abundo, R. Caronia, J. Liebmann, D. Steinberger, T. Krupin, L.F. Rosenberg, J.M. Rudermann, K. Clarkson, R. Weinreb, R. Ochabsi, M. Sherwood, M.F. Smith, D.W. Stokes, Z.S. Zam, J. Wilensky, D. Hillman, B. Kaplan, V. Gates, C. Nail, T. Zimmerman, R. Fechtner, R. Fenton, J. Fenton, E.J. Higginbotham, A.T. Johnson, Latanoprost, a Prostaglandin Analog, for Glaucoma Therapy: Efficacy and Safety after 1 Year of Treatment in 198 Patients Ophthalmology. ,vol. 103, pp. 1916- 1924 ,(1996) , 10.1016/S0161-6420(96)30407-7
Peter G. Watson, Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. ,vol. 105, pp. 82- 87 ,(1998) , 10.1016/S0161-6420(98)91372-0
Peter Watson, Johan Stjernschantz, A Six-month, Randomized, Double-masked Study Comparing Latanoprost with Timolol in Open-angle Glaucoma and Ocular Hypertension Ophthalmology. ,vol. 103, pp. 126- 137 ,(1996) , 10.1016/S0161-6420(96)30750-1
Niloofar Ziai, The Effects on Aqueous Dynamics of PhXA41, a New Prostaglandin F2α Analogue, After Topical Application in Normal and Ocular Hypertensive Human Eyes Archives of Ophthalmology. ,vol. 111, pp. 1351- 1358 ,(1993) , 10.1001/ARCHOPHT.1993.01090100059027
Carol B. Toris, Carl B. Camras, Michael E. Yablonski, Effects of PhXA41, A New Prostaglandin F2α Analog, on Aqueous Humor Dynamics in Human Eyes Ophthalmology. ,vol. 100, pp. 1297- 1304 ,(1993) , 10.1016/S0161-6420(93)31484-3
Carl B. Camras, Comparison of Latanoprost and Timolol in Patients with Ocular Hypertension and Glaucoma: A Six-month, Masked, Multicenter Trial in the United States Ophthalmology. ,vol. 103, pp. 138- 147 ,(1996) , 10.1016/S0161-6420(96)30749-5